147 related articles for article (PubMed ID: 38700643)
21. Going beneath the tip of the iceberg. Identifying and understanding EML4-ALK variants and TP53 mutations to optimize treatment of ALK fusion positive (ALK+) NSCLC.
Zhang SS; Nagasaka M; Zhu VW; Ou SI
Lung Cancer; 2021 Aug; 158():126-136. PubMed ID: 34175504
[TBL] [Abstract][Full Text] [Related]
22. Crizotinib for the treatment of ALK-rearranged non-small cell lung cancer: a success story to usher in the second decade of molecular targeted therapy in oncology.
Ou SH; Bartlett CH; Mino-Kenudson M; Cui J; Iafrate AJ
Oncologist; 2012; 17(11):1351-75. PubMed ID: 22989574
[TBL] [Abstract][Full Text] [Related]
23. Narrative review: immunotherapy in anaplastic lymphoma kinase (ALK)+ lung cancer-current status and future directions.
Schenk EL
Transl Lung Cancer Res; 2023 Feb; 12(2):322-336. PubMed ID: 36895933
[TBL] [Abstract][Full Text] [Related]
24. Identification of a novel HIP1-ALK fusion variant in Non-Small-Cell Lung Cancer (NSCLC) and discovery of ALK I1171 (I1171N/S) mutations in two ALK-rearranged NSCLC patients with resistance to Alectinib.
Ou SH; Klempner SJ; Greenbowe JR; Azada M; Schrock AB; Ali SM; Ross JS; Stephens PJ; Miller VA
J Thorac Oncol; 2014 Dec; 9(12):1821-5. PubMed ID: 25393796
[TBL] [Abstract][Full Text] [Related]
25. Molecular heterogeneity and co-altered genes in MET-amplified ALK-positive lung cancer: Implications for MET targeted therapy.
Dagogo-Jack I; Kiedrowski LA; Lennerz JK
Lung Cancer; 2023 Dec; 186():107383. PubMed ID: 37813016
[TBL] [Abstract][Full Text] [Related]
26. ALK and crizotinib: after the honeymoon…what else? Resistance mechanisms and new therapies to overcome it.
Rolfo C; Passiglia F; Castiglia M; Raez LE; Germonpre P; Gil-Bazo I; Zwaenepoel K; De Wilde A; Bronte G; Russo A; Van Meerbeeck JP; Van Schil P; Pauwels P
Transl Lung Cancer Res; 2014 Aug; 3(4):250-61. PubMed ID: 25806308
[TBL] [Abstract][Full Text] [Related]
27. Detection of ALK fusion variants by RNA-based NGS and clinical outcome correlation in NSCLC patients treated with ALK-TKI sequences.
Tabbò F; Muscarella LA; Gobbini E; Trombetta D; Castellana S; Rigutto A; Galetta D; Maiello E; Martelli O; Tiseo M; Scotti V; Ghilardi L; Gregorc V; Sergi C; Pilotto S; Del Conte A; Cappuzzo F; Cortinovis D; Osman G; Bareggi C; Di Maio M; Rossi A; Rossi G; Bria E; Volante M; Scagliotti GV; Graziano P; Novello S; Righi L
Eur J Cancer; 2022 Oct; 174():200-211. PubMed ID: 36044814
[TBL] [Abstract][Full Text] [Related]
28.
Ross JS; Ali SM; Fasan O; Block J; Pal S; Elvin JA; Schrock AB; Suh J; Nozad S; Kim S; Jeong Lee H; Sheehan CE; Jones DM; Vergilio JA; Ramkissoon S; Severson E; Daniel S; Fabrizio D; Frampton G; Miller VA; Stephens PJ; Gay LM
Oncologist; 2017 Dec; 22(12):1444-1450. PubMed ID: 29079636
[TBL] [Abstract][Full Text] [Related]
29. Impact of ALK variants on brain metastasis and treatment response in advanced NSCLC patients with oncogenic ALK fusion.
Qiao M; Zhao C; Liu Q; Wang Y; Shi J; Ng TL; Zhou F; Li X; Jiang T; Yang S; Gao G; Xiong A; Li J; Li W; Wu F; Chen X; Su C; Ren S; Zhou C; Zhang J
Transl Lung Cancer Res; 2020 Aug; 9(4):1452-1463. PubMed ID: 32953517
[TBL] [Abstract][Full Text] [Related]
30. Clinical characteristics and sequence complexity of anaplastic lymphoma kinase gene fusions in Chinese lung cancer patients.
Tian HX; Zhang XC; Yang JJ; Guo WB; Chen ZH; Wang Z; Wu YL
Lung Cancer; 2017 Dec; 114():90-95. PubMed ID: 29173772
[TBL] [Abstract][Full Text] [Related]
31. Therapeutic Sequencing in ALK
Elsayed M; Christopoulos P
Pharmaceuticals (Basel); 2021 Jan; 14(2):. PubMed ID: 33494549
[TBL] [Abstract][Full Text] [Related]
32. Role of
Zhou W; Yan LD; Yu ZQ; Li N; Yang YH; Wang M; Chen YY; Mao MX; Peng XC; Cai J
Oncol Lett; 2022 Jun; 23(6):181. PubMed ID: 35527776
[TBL] [Abstract][Full Text] [Related]
33. A novel SOS1-ALK fusion variant in a patient with metastatic lung adenocarcinoma and a remarkable response to crizotinib.
Chen HF; Wang WX; Xu CW; Huang LC; Li XF; Lan G; Zhai ZQ; Zhu YC; Du KQ; Lei L; Fang MY
Lung Cancer; 2020 Apr; 142():59-62. PubMed ID: 32114282
[TBL] [Abstract][Full Text] [Related]
34. Targeted therapies in non-small cell lung cancer: a focus on ALK/ROS1 tyrosine kinase inhibitors.
Sgambato A; Casaluce F; Maione P; Gridelli C
Expert Rev Anticancer Ther; 2018 Jan; 18(1):71-80. PubMed ID: 29187012
[TBL] [Abstract][Full Text] [Related]
35. Proteasome Inhibition Overcomes ALK-TKI Resistance in
Tanimoto A; Matsumoto S; Takeuchi S; Arai S; Fukuda K; Nishiyama A; Yoh K; Ikeda T; Furuya N; Nishino K; Ohe Y; Goto K; Yano S
Clin Cancer Res; 2021 Mar; 27(5):1410-1420. PubMed ID: 33310890
[TBL] [Abstract][Full Text] [Related]
36. A retrospective study of ensartinib-treated
Yuan X; Wang Y; Yang M; Wu P; Chen H; Yun Y; Shen Z; Ji D; Ma Y; Ding L
Lung Cancer Manag; 2023 Dec; 12(4):LMT61. PubMed ID: 38239813
[TBL] [Abstract][Full Text] [Related]
37. Molecular and clinical analysis of Chinese patients with anaplastic lymphoma kinase (ALK)-rearranged non-small cell lung cancer.
Zhou X; Shou J; Sheng J; Xu C; Ren S; Cai X; Chu Q; Wang W; Zhen Q; Zhou Y; Li W; Pan H; Li H; Sun T; Cheng H; Wang H; Lou F; Rao C; Cao S; Pan H; Fang Y
Cancer Sci; 2019 Oct; 110(10):3382-3390. PubMed ID: 31444835
[TBL] [Abstract][Full Text] [Related]
38. Clinical characteristics and targeted therapy of different gene fusions in non-small cell lung cancer: a narrative review.
Chen J; Xu C; Lv J; Lu W; Zhang Y; Wang D; Song Y
Transl Lung Cancer Res; 2023 Apr; 12(4):895-908. PubMed ID: 37197619
[TBL] [Abstract][Full Text] [Related]
39. Crizotinib: a novel and first-in-class multitargeted tyrosine kinase inhibitor for the treatment of anaplastic lymphoma kinase rearranged non-small cell lung cancer and beyond.
Ou SH
Drug Des Devel Ther; 2011; 5():471-85. PubMed ID: 22162641
[TBL] [Abstract][Full Text] [Related]
40. Durable Complete Response to Alectinib in a Lung Adenocarcinoma Patient With Brain Metastases and Low-Abundance
Zhu Y; Jia R; Shao YW; Zhu L; Ou Q; Yu M; Wu X; Zhang Y
Front Oncol; 2020; 10():1259. PubMed ID: 32850382
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]